Cardiol Therapeutics, Inc. (CRDL)

NASDAQ: CRDL · IEX Real-Time Price · USD
2.00
0.28 (16.28%)
At close: Jan 14, 2022 4:00 PM
2.01
0.01 (0.50%)
After-hours:Jan 14, 2022 7:52 PM EST
Market Cap120.87M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out60.44M
EPS (ttm)-0.74
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,332,858
Open1.80
Previous Close1.72
Day's Range1.77 - 2.08
52-Week Range1.55 - 4.96
Beta1.06
AnalystsBuy
Price Target7.23 (+261.5%)
Earnings DateNov 15, 2021

About CRDL

Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary...

IndustryDrug Manufacturers-Specialty & Generic
Founded2017
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolCRDL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CRDL stock is "Buy." The 12-month stock price forecast is 7.23, which is an increase of 261.50% from the latest price.

Price Target
$7.23
(261.50% upside)
Analyst Consensus: Buy

News

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering

Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing a...

2 months ago - Newsfile Corp

CRDL Stock: 7 Things to Know About Healthcare Play Cardiol Therapeutics

Today, CRDL stock is down despite very positive news of a Health Canada approval for a Phase 2 trial of the company's leading drug. The post CRDL Stock: 7 Things to Know About Healthcare Play Cardiol Th...

2 months ago - InvestorPlace

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

Oakville, Ontario--(Newsfile Corp. - October 25, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing i...

2 months ago - Newsfile Corp

Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors

Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing ...

4 months ago - Newsfile Corp

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial...

Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing in...

4 months ago - Newsfile Corp

Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop

As we begin another week, here's a look at some of the best short squeeze stocks available to investors according to research from Fintel. The post Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts ...

Other symbols:NAOVVRPXBTBT
4 months ago - InvestorPlace

Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"

Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-in...

5 months ago - Newsfile Corp

Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman

Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on devel...

6 months ago - Newsfile Corp

Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting

Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on deve...

6 months ago - Newsfile Corp

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT

Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on deve...

6 months ago - Newsfile Corp

Cardiol Therapeutics Closes $22 Million Bought Deal Offering

Oakville, Ontario--(Newsfile Corp. - May 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-infl...

8 months ago - Newsfile Corp

Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients ...

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, On...

8 months ago - Newsfile Corp

Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of Card...

Results expected to support the Company's plans to file an IND application with the FDA for a Phase II international trial in acute myocarditisOakville, Ontario--(Newsfile Corp. - April 12, 2021) - Card...

9 months ago - Newsfile Corp

Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A

Oakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on deve...

9 months ago - Newsfile Corp

Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer

Oakville, Ontario--(Newsfile Corp. - March 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on dev...

9 months ago - Newsfile Corp

Cardiol Therapeutics stellt Antrag auf Nasdaq-Uplisting und erzielt Erlöse von mehr als 10 Mio. USD aus der Ausübung ...

Oakville, Ontario--(Newsfile Corp. - Dienstag, 2. März 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" oder das "Unternehmen"), ein Biotechnologieunternehmen im klinis...

10 months ago - Newsfile Corp

Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exe...

Oakville, Ontario--(Newsfile Corp. - March 2, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on deve...

10 months ago - Newsfile Corp

Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III ...

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, On...

11 months ago - Newsfile Corp

Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences

Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing in...

1 year ago - Newsfile Corp

Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx(TM)

Study results are expected to support the Company's plans to file an IND application with the FDA for a Phase II clinical trial in acute myocarditisOakville, Ontario--(Newsfile Corp. - December 22, 2020...

1 year ago - Newsfile Corp